Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Canine distemper virus docking protein mapped
The researchers hope their insights will lead to the development of antiviral drugs.
The research could help scientists create antiviral drugs for CDV and measles.

A new study has revealed the structure of the docking protein of the canine distemper virus (CDV), potentially allowing the development of antiviral drugs which would target the protein and prevent the virus from entering host cells.

As CDV is related to measles, both belonging to the genus Morbillivirus, the study could also help inform the development of an antiviral drug which could protect humans from measles.

Although vaccines exist for both diseases, worldwide 100,000 people still die each year from measles and CDV can cause epidemics in wild animals as well as affecting domestic dogs in areas where there is limited vaccination.

The researchers from the University of Bern and the Zurich University of Applied Science used cry-electron microscopy (cryo-EM) to map the viruses’ H-Protein, also known as the docking protein, at molecular level, revealing that the protein has three main domains (heads, neck and stalk) in an asymmetric structure.

Knowledge of this structure could be used to develop antiviral drugs which would block the docking protein. The researchers involved in the study, alongside scientists from the University of Marseille, have already successfully identified antibodies that can neutralise CDV.

Dimitrios Fotiadis, one of the co-authors of the study, said: “The fact that we were able to determine the structure represents a big leap forward. This now allows us to understand how the different subdomains spatially organize with each other - and provides us with a valuable blueprint to develop next-generation antiviral drugs that block the 'docking protein’.”

Philippe Plattet, another of the co-authors, said: "Simultaneously blocking the cell entry process in distemper and measles virus with several different neutralizing molecules is a promising antiviral strategy.”

The study was published in Proceedings of the National Academy of Science USA.

Become a member or log in to add this story to your CPD history

Antibiotic Amnesty survey opens

News Story 1
 The Responsible Use of Medicines Alliance - Companion Animal and Equine (RUMA - CA&E) has launched a survey which seeks to measure the success of this year's Antibiotic Amnesty campaign.

Its results will help the group to calculate how many unused or out-of-date antibiotics were returned as part of the campaign throughout November. Practices are also asked how they engaged with clients to raise awareness of the issue.

Participating practices can enter a prize draw to win up to 100 in vouchers for taking part. Further prizes from BSAVA and Webinar Vet will be available for practices with the best input.

The survey takes a few minutes to complete and will be running throughout December. It can be accessed via this link

Click here for more...
News Shorts
Bluetongue cases lead to restricted zone extension

Following the detection of new cases of bluetongue virus serotype 3 (BTV-3), the restricted zone has been extended to include additional parts of Hampshire, Wiltshire, Oxfordshire and North Yorkshire, as well as Bournemouth, Christchurch, Poole and part of Dorset.

The zone now covers 28 counties and unitary authorities in England. As of 16 December, 185 cases of BTV-3 have been confirmed in England and Wales during the current vector period.

Bluetongue is a notifiable disease. Suspected cases must be reported on 03000 200 301 in England or 03003 038 268 in Wales. In Scotland, suspected cases should be reported to the local field services office. Suspected cases in Northern Ireland should be reported to the DAERA Helpline on 0300 200 7840 or by contacting the local DAERA Direct Veterinary Office.

A map of the area where movement restrictions apply can be found here.